Melnyk V. Clinical and Experimental Substantiation of Treatment of Optic System Damage in Patients with Relapse-remitting Type of Multiple Sclerosis (Clinical and experimental research)

Optic system damage in patients with relapse-remitting type of multiple sclerosis is an actual problem of modern medicine. Optic neuritis is the first manifestation of multiple sclerosis in 75% patients. Absence of the effective treatment is the reason of search of new means in patients with optic neuritis. Intravenous immunoglobulin decreases acute period and prolongs remission of multiple sclerosis. There are no data about their action on optic neuritis course. We investigated intravenous immunoglobulin action on optic nerve and occipital part of brain in rats with experimental allergic encephalitis (EAE) and on optic neuritis course in patients with multiple sclerosis. Use of "Immunoglobulin normal human pro injectionibus intravenosa" and Rat's immunoglobulin decreases demyelization of optic nerve fibers, damage of nerve cells and blood vessels of occipital part of brain in animals with EAE. Use of "Immunoglobulin normal human pro injectionibus intravenosa", in dose 0,2 g/kg per day during 5 days and then 0,2 g/kg per month during two years, increases visual functions (visual acute, contrast vision, visual field on monochromic, red and green color, etc.) on 60-90% and decreases visual evoked potential latency on 78% in patients with optic neuritis, caused by relapse-remitting type of multiple sclerosis. Use of "Immunoglobulin normal human pro injectionibus intravenosa" decreases immunological activity on 17-36% and decreases frequency of emphasizes of optic neuritis on 78% in patients with relapse-remitting type of multiple sclerosis.